Advent International, a private equity firm based in Boston, Massachusetts, is considering a buyout deal for drugmaker Swedish Orphan Biovitrum.
Advent has approached other buyout firms including Permira in an attempt to lead a consortium for the acquisition of the Swedish biotech firm.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
It is also weighing to bring in sovereign wealth funds for the bid. The talks are at an early stage, and it is not yet clear that they will ultimately lead to a deal, according to the people.
Source: Seeking Alpha
Can’t stop reading? Read more
Triton and Carlyle weigh bids for German industrial group REMA Tip Top
Triton and Carlyle weigh bids for German industrial group REMA Tip Top Triton Partners and Carlyle...
EQT targets €23bn for flagship EQT XI fund as fundraising cycle begins
EQT targets €23bn for flagship EQT XI fund as fundraising cycle begins EQT has officially set the...
Private equity fast-tracks finance grads amid Wall Street slowdown
Private equity fast-tracks finance grads amid Wall Street slowdown Private equity firms are...